In breast cancer datasets, we observe elevated expression of <i>SOX9</i> and <i>SEMA7A</i> in triple-negative breast cancers, as well as in the mesenchymal subtype of triple-negative breast cancers, suggesting disruption of this regulatory axis in breast cancer. Here, SOX9 is linked to breast cancer.